DR info

臨床試験数 : 9 / 薬物数 : 14 - (DrugBank : 7) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 16

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Allogeneic Mesenchymal Stem Cells
   Stempeutics Research Pvt Ltd
      2012   Phase 2   NCT01484574   India;
Bosentan
   Hospital Universitario Getafe
      2009   -   NCT01447550   Spain;
CLBS12
   Caladrius Biosciences, Inc.
      2017   Phase 2   NCT02501018   Japan;
Erythropoietin
   EVEETA Study Group
      2016   -   JPRN-UMIN000021374   Japan;
G-CSF
   Regenerative Medicine Unit, Division of Vascular Regeneration Therapy, Institute of Biomedical Research and Innovation (IBRI)
      2011   -   JPRN-UMIN000005227   Japan;
Ginkgo biloba
   First Clinical Center of Chinese PLA General Hospital
      2021   Phase 0   ChiCTR2100048104   China;
Heparin
   First Clinical Center of Chinese PLA General Hospital
      2021   Phase 0   ChiCTR2100048104   China;
RNL-Vascostem®
   R-Bio
      2007   -   NCT01302015   Korea, Republic of;
SOC
   Caladrius Biosciences, Inc.
      2017   Phase 2   NCT02501018   Japan;
Selexipag
   Actelion
      2021   -   NCT04914247   -
Stempeucel(R)
   Stempeutics Research Pvt Ltd
      2017   Phase 2   NCT03056742   India;
Thrombopoietin
   EVEETA Study Group
      2016   -   JPRN-UMIN000021374   Japan;